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INTRODUCTION 
  Carcinoma  stomach remains the leading cause of death in 
both developed and developing countries with mortality ranks 
second in the world. Early stages of tumour are amenable to 
surgical correction, but usually the patients presents in advanced 
stage with signs of inoperability. Inspite of newer modalities of 
therapies  available for  treatment, survival rate is poor in advanced 
stage .  
  The genesis of molecular biology led to the  development 
of newly designed therapeutic molecules, which interferes with the 
pathogenesis of cancer cells. The Human epidermal growth 
receptor 2 gene (Her-2, otherwise called as ERBB 2 and Her-2 nu) 
is now considered as the cornerstone in solid human cancers, 
especially gastric cancer. 
There is now a strong  correlation that exists between  Her-2 
overexpression and poor outcome in gastric cancer patients, which 
has been  evidenced by many international studies.  
Most of the studies regarding Her-2 is from the foreign 
literature. This study is an attempt to analyse Her-2 positivity in 
gastric carcinoma patients at MADURAI GOVERNMENT  
RAJAJI  HOSPITAL which primarily caters the rural population in 
and around MADURAI. 
 
 
 
 
 
 
 
 
 
 
 
AIMS & OBJECTIVES 
 
1. To assess Her-2/neu content in our gastric cancer 
patients.       
2. To assess the correlation between this receptor tumour 
content and clinicopathologic characteristics. 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
INCIDENCE  
     Gastric cancer is the fourth most common type of cancer 
worldwide, preceded by lung, breast and colorectal cancers. The 
incidence rate of this disease presents considerable variation 
according to age, gender, socio-economical conditions and 
geographical  location. Thus, most of the gastric cancer patients are 
older than 50 years at the time of diagnosis , and the global 
incidence is two times more common  in men than in women. The 
most substantial variations in the incidence rates of this malignancy 
are, however, observed in relation to geographical regions.   
     In general, the incidence of gastric cancer is high in Asian and 
European populations, while it is low in American and Australian 
population. Nearly seventy percentage of gastric cancer occurs in 
developing countries. Gastric cancer exhibits worldwide 
distribution and in not specific to  any geographical pattern. Among 
the Asian countries China, Japan, Korea harbour the high risk for 
gastric cancer with other Asian countries comes under low risk .  
         In India it ranks fifth in men and seventh in women as a 
leading cause of  death. Highest incidence is noted in southern and 
north-east parts of India with maximum number of cases reported 
in MIZORAM. 
 
TIME TRENDS IN INCIDENCE:  
       The incidence rates for gastric cancer have undergone a steady  
decline during the past decades. This downward trend is equally 
observed among both sexes and in high and low risk areas, but has 
been more pronounced in developed countries. Interestingly, the 
fall in the incidence is particularly associated to distal gastric 
carcinoma, in contrast to proximal cancer that seems to experience 
a permanent slight increase. Similarly, epidemiological studies 
have shown that the general decrease in incidence is mainly 
attributed to the fall in intestinal subtype of gastric cancer  while the 
diffuse subtype shows a rather small change.  
        The reasons underlying the generalized decline in the 
incidence of this malignancy are not well understood, but it has 
been hypothesized that this may be associated to newer techniques 
in the processing and preservation of food, better nutrition and 
reduced transmission of H. pylori in childhood. 
       Despite the notable fall in the incidence rate, the absolute 
number of cases of gastric cancer continues to increase globally as 
a result of the population growth and ageing. In the year 1980 
gastric cancer was the most common type of cancer globally, with 
approximately 669350 new cases diagnosed, representing 10.5% of 
the cancer burden. Ten years later, in 1990, approximately 798500 
new cases occurred. 
         For the year 2000, the number of new cases of gastric cancer 
reached 876000.  In 2002, the number of new cases was estimated 
to be 934000, which meant 8.6% of the total number of cancer 
cases. For 2010, the number of new cases of gastric cancer is 
expected to be 1.1 million.  
  
MORTALITY AND SURVIVAL: 
               Following lung cancer, carcinoma stomach ranks second 
cause of mortality worldwide , accounting for nearly 700000 deaths 
in 2002. Wide geographical variation in mortality rates exist 
throughout the world, particularly high in the developing world. 
Similar to the incidence, a constant rate of decline in mortality in 
both sexes, and in low and high risk countries has occurred in the 
last decade. 
          The decline in mortality, however, seems to occur faster than 
with the incidence, and is particularly pronounced in certain 
populations. Mortality rate are notably high because in most cases, 
the disease is diagnosed at advanced stages when the treatment is 
likely to fail. In general, the five-year survival for patients of 
gastric cancer is below 30% in most countries, despite some 
variations according to the country/geographical region. 
           It is noteworthy, however, that the survival rate have 
reached more than 50% in the last decade among Japanese. This is 
thought to be associated with the implementation of X-ray 
(photofluorography) based gastric cancer mass screening programs 
since early in 1960´s.  
         Similar experience with X-ray based mass screening 
interventions in other high risk countries have demonstrated a 
significant impact of early detection in the mortality of gastric 
cancer. Nevertheless, studies in population groups with same ethnic 
background but dissimilar access to health care suggest that 
environmental and biological factors may also play an important 
role in explaining differences in mortality and survival of gastric 
cancer between high and low risk countries or developing versus 
developed economies. 
 
HISTOLOGICAL AND ANATOMICAL CLASSIFICATION 
OF GASTRIC CANCER 
 
         Various classifications have been designed for carcinoma 
stomach on the basis of macroscopic or histological features, which 
include Borrman, Japanese system, World Health Organization 
(WHO) system and Lauren. The Lauren classification system is 
most commonly used and describes the tumors in relation to 
microscopic configuration and growth pattern. 
        According to the Lauren system, gastric cancer is divided into 
intestinal and diffuse histological subtype. These two subtype 
present marked differences in pathology, epidemiology, etiology 
and biological behavior. Intestinal subtype gastric cancer is the 
most frequent globally and is particularly common in geographical 
regions with high-risk of the malignancy.        
INTESTINAL SUBTYPE: 
       Intestinal subtype tumors are often localized in the lower part 
of the stomach (antrum), and are characterized by having well 
defined glandular formation, similar to the microscopic appearance 
of colonic mucosa. The development of intestinal subtype gastric 
cancer follows a stepwise sequence of precursor lesions starting 
with superficial gastritis, continuing through chronic atrophic 
gastritis, followed by intestinal metaplasia and dysplasia and 
progress to overt carcinoma. 
        For unknown reasons, the multistep process often does not 
lead to neoplasia, as it stops at one of the stages and undergoes 
regression. The aetiology of intestinal subtype gastric cancer is 
mainly associated to environmental factors, the tumour frequently 
develops late in life (after 50 years of age), and is twice more 
common in males than females.              
 
 
DIFFUSE SUBTYPE:       
  Diffuse subtype gastric cancer commonly develops in the 
corpus of the stomach which do not have any glands and cellular 
adhesion, with small clusters of neoplastic cells infiltrating the 
stomach wall uniformly. No pre-neoplastic lesions have been 
observed during the development of diffuse cancers. 
           Diffuse subtype tumours are commonly associated with 
genetic predisposition, and  single-cell mutations in normal gastric 
glands. The diffuse subtype has a relatively constant or even 
slightly increase in incidence rates, more often occurs in younger 
individuals and presents a similar prevalence in males and females, 
and is associated with a poor prognosis than the intestinal subtype.        
 
ANATOMICAL LOCATION: 
       The anatomical location of tumour in the stomach is 
considered as an important parameter for the classification of 
gastric cancer. On the basis of anatomical location two subtypes of 
gastric cancer can be distinguished: tumours from the distal region 
of the stomach  and those arising at the most proximal part of this 
organ. These two anatomical subtype of tumours present 
remarkable etiological differences. Non-cardia cancer is generally 
thought to develop as a result of the interaction between host, 
environmental and H. pylori factors. 
           In contrast, two etiological mechanisms have been proposed 
for cardia gastric cancer. One is associated with atrophic gastritis 
and resembles the development of non-cardia malignancies. The 
second arises in similar fashion to oesophageal carcinomas, as a 
result of frequent refluxing of acidic gastric juice into the distal 
oesophageal mucosa, which leads to the transformation from 
squamous to columnar  metaplastic epithelium to, ultimately, overt 
cancer. Epidemiological dissimilarities also exist between these 
two anatomical subtypes of gastric tumours. Non-cardia gastric 
cancer accounts for the majority of the cases worldwide and is the 
predominant type in high-risk areas. In contrast, cardia cancer is 
more homogeneously distributed all over the world and its 
incidence tends to be increasing. 
 
 
RISK FACTORS FOR GASTRIC CANCER 
        Several parameters were correlated as risk factors, which by 
establishing complex interactions may ultimately lead to 
development of this malignancy. Among the most recognized 
gastric cancer risk factors are nutritional and dietary aspects, 
genetic predisposition and sporadically occurring mutations, and 
Helicobacter pylori infection. More recently, aspects related to the 
inflammatory response against the bacterial infection have emerged 
as important determinants for the risk of this malignancy. 
 Dietary and nutritional aspects 
           Diet plays a dual role in gastric cancer aetiology, providing a 
number of elements and vitamins that reduce the formation of 
carcinogens, but also as the source of well established carcinogenic 
molecules or precursors of them. Evidence indicates that diet high 
in fruits and vegetables may protect against gastric cancer while 
salted foods, consumption of processed foods and inappropriate 
preservation and storage of aliments could increase the risk of this 
malignancy.  
          In general, epidemiological studies show a favourable 
outcome with consumption of fruits and vegetables and gastric 
cancer, which seems to be more pronounced in case of citrus fruits 
and raw allium vegetables. It has also been suggested that fruits 
may have stronger potential than vegetables to protect against 
gastric cancer development. These associations differ according to 
anatomical and histological subtypes of gastric malignancies, sex 
and lifestyle behaviours (e.g. smoking and alcohol consumption). 
On the basis of the existing evidence, the International Agency for 
Research on Cancer (IARC/WHO) has considered that high intake 
of fruits and high intake of vegetables reduce the risk of gastric 
cancer. Still, it remains unknown which constituents in fruit and 
vegetables specifically protect against the development of this 
malignancy. 
             Epidemiological studies have evaluated the association 
between specific antioxidant nutrients known to reduce the 
formation of carcinogenic molecules and the risk of gastric cancer. 
In general, antioxidant molecules such as lycopene, vitamin A, 
vitamin E, vitamin C and micro-nutrients like selenium found to 
decrease the risk of carcinoma stomach. But the association 
between β-carotene, vitamin A and vitamin E and gastric cancer is 
more controversial. As in the case of fruits and vegetables, the 
potential significance of antioxidant nutrients as protector factors 
varies substantially depending on the anatomical and histological 
subtype of gastric cancer, sex, lifestyle behaviours and interactions 
between antioxidant molecules. 
        Diets high in salt and preserved meats have been suggested to 
play a role in the aetiology of gastric cancer. Salt may act as an 
irritant of the stomach wall and in connection to H. pylori infection 
may contribute to the damage of the mucosal layer, enhancing thus 
the susceptibility of epithelial cells to carcinogenic molecules that 
accumulate in this organ. Meat products like bacon, sausage, salami 
and ham are often rich in salt, nitrite, nitrosamines, and can also be 
the source of N-nitroso compounds, of established carcinogenic 
properties. A number of case-control and cohort studies have found 
that higher consumption of red meat and salted foods resulted in 
increased risk of carcinoma stomach.  
 
 
Genetics in gastric cancer 
 
       Genetics play a fundamental role for the origin and progression 
of carcinoma stomach. It is well established that a number of 
inherited germ-line mutations and genetic syndromes predispose to 
the development of this malignancy. Likewise, a diverse set of 
genetic and epigenetic de novo alterations are often found in gastric 
cancer, which probably occur at different stages during the 
development of the malignancy, and differ according to the 
histological subtype of the disease. Familial clustering of cases is 
reported in ten percent of population, in which two or more 
relatives from the same family are affected.                                                            
              In general, the risk of first degree relatives developing 
carcinoma stomach is expected to be 2 to 3 fold higher than in 
persons with no familiar background of the disease. This, however, 
should be cautiously analyzed due to the fact that, besides the 
common genetic background, environmental and cultural factors 
(e.g. H. pylori, diet, lifestyle behaviours) may be similarly shared 
among the family members and in some cases are difficult to 
differentiate. Nevertheless, the genetic susceptibility to develop this 
malignancy has been clearly established in a fraction of these 
familial-clustered gastric cancers. 
Germ-line mutation:    
                Mutations involving the E-cadherin gene (CDH1) are the 
most recognized genetic aberrations found in hereditary gastric 
cancer, accounting for approximately 1-3% of the cases. Epithelial 
cells express high content of  E-cadherin and exerts cellular 
adhesion and suppression of invasion. CDH1 associated familial 
gastric cancer follows an autosomal dominant pattern of 
inheritance, with more than 70% penetrance, and is caused by 
several alterations in the CDH1 gene, mainly truncating mutations.          
           Most of the gastric cancer cases attributed to CDH1 
aberrations are of diffuse subtype, particularly signet-ring cell 
adenocarcinomas, and are predominantly observed in young 
individuals. A considerable number of genetic and epigenetic 
alterations have been identified both in preneoplastic lesions 
leading to gastric cancer and neoplasia itself. These spontaneously 
occurring events can trigger aberrant effects at several molecular 
levels, including reactivation of telomerase, activation of 
oncogenes, inactivation of tumour suppressor genes, over-
expression of growth factors and cytokines, altered expression of 
cell-cycle regulators and DNA-repairing enzymes, and increased 
microsatellite instability. It is worth noting that genetic and 
epigenetic events may alter the expression of known oncogenes   
(c-met, K-ras), tumour suppressor genes (APC, p53), DNA-
repairing enzymes (hMLH1) and cell-adhesion molecules (E-
cadherin, β-catenin, γ-catenin) that are central for the cellular 
homeostasis.  
 Somatic mutation:          
        Many types of  somatic mutation  in gastric cancer have been 
described in at the molecular level. The mechanisms behind this 
type of mutation are not fully established. The p53 gene is mutated 
in 60% of gastric cancer. Overexpression of p53 can be identified 
by immuno-histochemistry techniques but the its association with 
regard to prognosis was not clear.   
           A target of amplification on 17q in gastric cancers was also 
identified using a combination of comparative genomic 
hybridization and oligonucleotide microarray studies.        
            Overexpression of  DARP32 and a novel isoform t-DARP 
were both found in many cases of gastric cancer . PCR has detected  
no   somatic mutations of p16
INK4  
among 60 cases with gastric 
cancer . On the other hand, p16
INK4
 somatic mutations were noted 
along with loss of heterozygosity of 9p in several oesophageal 
adenocarcinomas, which are related to gastroesophageal junctional 
cancers. Other cases of these cancers were observed to have loss of 
p16 expression. In a study of p16's promoter region in gastric 
cancers, a significant number (41%) exhibited CpG island 
methylation. Many cases with hypermethylation of promoter 
regions displayed the MSI-H phenotype and multiple sites of 
methylation, including the hMLH1 promoter region. 
 Evidence of a tumor suppressor locus on chromosome 3p has 
accumulated from a variety of studies and includes allelic loss at 3p 
in primary gastric tumours and homozygous deletion of 3p in a 
gastric cancer cell line . The FHIT gene was isolated from the 
common fragile site region (FRA3B) at 3p14.2 and found to have 
abnormal transcripts with deleted exons in five of nine gastric 
cancers. Furthermore, loss of FHIT protein expression was 
demonstrated immunohistochemically in the majority of gastric 
carcinomas in one study. Also, a somatic missense mutation was 
identified in exon 6 of the FHIT gene during a coding region 
analysis of 40 gastric carcinomas. Additional studies are needed to 
identify the critically altered targets on chromosome 3p and clarify 
the role that FHIT plays in gastric tumorigenesis.  
        Deletion of the trefoil peptide TFF1 has been found in 60% of 
gastric cancer. Mice with homozygous deletion of Tff1 by 
homologous recombination all developed antral dysplasia, and 30% 
were reported to have multifocal gastric carcinoma. 
             Loss of p27, a cell-cycle regulator,  correlates  with 
advanced stage in gastric cancer. Amplification and overexpression 
of the c-met gene, which encodes a tyrosine kinase receptor for the 
hepatocyte growth factor, have been reported in gastric carcinomas, 
and the epidermal growth factor and its receptor are expressed in 
approximately one-fourth of gastric cancers. Alterations of 
fibroblast found  by a polymerase chain reaction based assay in 
carcinoma stomach correlated with worst prognosis. Amplification 
of c-erbB-2 has been demonstrated in a small subset  of gastric 
cancers and overexpression observed correlates with worst 
prognosis.  The expression of angiogenesis factors such as vascular 
endothelial growth factor has been observed in a subset of gastric 
cancers, indicating the potential role of angiogenesis inhibitor 
therapy. Membrane-type matrix metalloproteinase is preferentially 
expressed in some gastric cancer cells with co-localization and 
activation of the zymogens proMMP-2. Advanced gastric cancer 
patients express increased activation of plasminogen. Specific 
alterations such as these need true prevalence determination and 
further characterization in gastric cancer before genetic tests can be 
designed for clinical use. 
       In addition, they are molecules that have been consistently 
linked with the development and progression of other types of 
cancer. These gene dysregulations are likely to occur during the 
course of the multistep gastric carcinogenesis as a result of 
replication errors, mutations, amplifications, defective DNA-repair, 
aberrant methylation, loss of heterozygosity (LOH), or a 
combination of two alterations. 
CLINICAL FEATURES: 
Gastric cancers, when superficial and surgically curable, 
usually do not produce any symptoms. As the tumour becomes 
more extensive, patients may complain of an insidious epigastric 
discomfort, early satiety to a severe and constant upper abdominal 
pain. Loss of appetite, nausea and vomiting is very common but is 
not the usual presenting complaint. 
  Weight loss may commonly be observed, and nausea and 
vomiting are particularly prominent with tumours of the pylorus; 
dysphagia and early satiety may be the major symptoms caused by 
diffuse lesions originating in the cardia. There are no early 
recognisable physical signs. A palpable abdominal mass indicates a 
long-standing growth and predicts regional extension. 
  Metastases commonly occurs to the intraabdominal organs ,  
supraclavicular lymph nodes, ovary, periumbilical region, 
peritoneum and rectum. Malignant ascites may also develop. The 
liver is the most common site for hematogenous spread of tumor. 
The presence of iron-deficiency anaemia and of occult blood 
in the stool  mandates a search for an occult gastrointestinal tract 
lesion.                                                                  
Other clinical features associated with gastric 
adenocarcinomas include migratory thrombophlebitis, micro- 
angiopathic hemolytic anaemia, diffuse seborrheic keratoses          
(so-called Leser-Trélat sign), and acanthosis nigricans. 
INVESTIGATIONS: 
The main modalities of investigating gastric adenocarcinoma 
and thus guiding therapy are 
1. ENDOSCOPY AND ENDOSCOPIC ULTRASOUND: 
 Flexible endoscopy remains the essential tool for 
diagnosis of gastric cancer. It allows visualisation of the tumour, 
provides tissue for pathologic diagnosis, and can serve as a 
treatment for patients with obstruction and bleeding. Increasingly, 
flexible endoscopy combined with ultrasound is being used to stage 
and risk-stratify patients with gastric cancer properly. The 
predictive accuracy of EUS for T and N stages was found to be 
58% and 50% respectively. Its role in the evaluation of metastatic 
disease is currently limited. 
2.  COMPUTED TOMOGRAPHY: 
 CT remains the primary method for detection of intra-
abdominal metastatic disease, with an overall detection rate of 
approximately 85%. The ability to image peritoneal metastases 
remains only 50%. The accuracy of T and N stages determined by 
CT is less accurate than EUS. 
3. POSITRON EMISSION TOMOGRAPHY: 
 PET is not currently a primary staging modality for gastric 
cancer. Only 50% of gastric cancers are PET avid, which limits its 
application. However, PET positive patients are presumed to have 
advanced disease and are considered for neoadjuvant therapy. It 
may be an effective modality for monitoring response to therapy.    
 4. LAPAROSCOPY: 
 The high rate of occult metastatic disease makes laparoscopy 
an attractive staging modality. The overall sensitivity of 
laparoscopy for detecting metastatic disease was higher than 95%.  
Unresectable disease not detected by prior imaging was found in 
35% of gastric cancer patients undergoing staging laparoscopy. 
More than 70% of these patients had occult peritoneal or liver 
metastasis. 
5. TUMOUR MARKERS:  
             
        The carcinoembryonic antigen (CEA) level is elevated in 
approximately one-third of patients with primary gastric cancer. 
The sensitivity of CEA as a marker of gastric cancer is low, but 
when the CEA level is elevated, it generally correlates with stage. 
Combining CEA with other markers, such as the sialylated Lewis 
antigens CA19-9 or CA50, can increase sensitivity, compared with 
CEA alone.  
            A large study of patients with gastric cancer evaluated the 
prognostic significance of serum levels of CEA , alpha-fetoprotein , 
human chorionic gonadotropin, CA19-9 , and CA125 , as well as 
tissue staining for C-erb B-2  and Î²-HCG . In a multivariate 
analysis, only a serum Î²-HCG level of 4 IU/L or greater and 
CA125 level of 350 U/mL or greater  had prognostic significance. 
             Elevated serum Î²-HCG and CA125 levels in gastric cancer 
before chemotherapy may reflect not just tumour burden but also 
aggressive biology; however, the utility of these markers in staging 
must be compared to that of other known preoperative markers of 
stage, such as on T- and N-stage endoscopic ultrasonography. 
 
 
 
 
 
         
 
 
 
TNM STAGING OF CARCINOMA STOMACH: 
Stage TNM Features 
0 TisN0M0 Node negative; limited to mucosa 
IA T1N0M0 Node negative; invasion of lamina propria or 
submucosa 
IB T2N0M0 
T1N1M0 
Node negative; invasion of muscularis propria 
II T1N2M0 
T2N1M0 
Node positive; invasion beyond mucosa but within 
wall 
  Or 
 T3N0M0 Node negative; extension through wall 
IIIA T2N2M0 
T3N1-2M0 
Node positive; invasion of muscularis propria or 
through wall 
IIIB T4N0-1M0 Node negative; adherence to surrounding tissue 
IIIC T4N2-3M0 
T3N3M0 
>3 nodes positive; invasion of serosa or adjacent 
structures 
7 or more positive nodes; penetrates wall without 
invading serosa or adjacent structures 
IV T4N2M0 Node positive; adherence to surrounding tissue 
  or  
 T1-4N0-2M1 Distant metastases 
Abbreviation: ACS, American Cancer Society; TNM, tumor, node, metastasis 
 
HER2 BIOLOGY 
 The Her-2 protein (p185, Her-2/neu, ErbB-2) has a 
molecular weight of 185- KDa transmembrane tyrosine kinase 
receptor and belongs to the family of EGFRs . This family is 
consists of four types: HER1, HER2, HER3, HER4.These receptors  
consists of an ligand binding domain situated extracellularly, a 
small transmembrane domain, and a domain with tyrosine kinase 
activity present intracellularly. The binding of different substances 
to the extracellular domain initiates a series of events that resulted 
in proliferation of cancer cells, cell death, cell to cell adhesion, 
cellular differentiation and migration. 
 The gene for Her-2 is present in the chromosome 17q2 1 
which is situated adjacent to topoisomerase IIa genes . It bears 
direct relationship with oncogene V-erbB of the avian 
erythroblastosis virus. 
 In carcinomas Her-2 is considered as an oncogene because  
amplification of this gene induces  protein overexpression in the 
cellular membrane and as a result it acquires the properties of a 
malignant cell.  
HER-2 AS A PROGNOSTIC FACTOR  
       Various studies enumerating the prognosis of gastric cancer 
have been conducted across the world. In Japanese studies, 
conducted among 200 patients Her-2 positivity was noted in 23%  
by IHC. 13% positivity was noted among 166 patients in Spanish 
group. The median survival was poor for patients with  Her-2 
overexpression by IHC when compared with Her-2 negative 
patients in both of these studies. This shows Her-2 overexpression 
as an independent predictor of mortality. It is considered as the 
second poorest prognostic factor after lymph node status in early 
stage of the tumour. Her-2 staining intensity was also correlated 
with the metastasis to lymph node, invasion of serosa and size of 
tumour.  
      Allgayer showed a increased rate of membranous or 
cytoplasmic Her-2 expression by IHC among 203 gastric cancer 
patients. He also concluded Her-2 expression as a poorest 
prognostic factor. This was further confirmed by the studies 
conducted by Tanner who showed that  median survival of patients 
with Her-2 negativity was one year, while patients with Her-2 
positivity had only median survival of six months.  
HER-2 AND E-cadherin EXPRESSION 
         The E-cadherin mediated cell adhesion system acts as an 
invasive suppressor system, and tumours which expresses  E-
cadherin frequently had lymph node involvement and metastasis to 
different sites. This abnormal E-cadherin expression seems to be an 
early event in tumorigenesis. 
        The diffuse type of gastric cancer is usually associated with 
decreased expression of the E-cadherin molecule. Direct evidence 
of an E-cadherin mutation that triggers tumorigenesis has been 
associated with detection of germ line mutation of the gene CDH1 
in hereditary diffuse gastric cancer. This molecule is down 
regulated in sporadic diffuse type gastric cancers because of a 
somatic mutation or hypermethylation of the promotor region in the 
early stages of tumorigenesis. 
HER-2 AND MICROSATELLITE INSTABILITY: 
Microsatellite instability (MSI) comprises length mutation in 
tandem oligonucleotide repeats. It is a hallmark of replication error 
phenotype observed in some sporadic tumours from different sites. 
In human, atleast six proteins (hMLH1, hMSH2, hPMS1, hPMS2, 
hMSH6 and hMLH3) comprise the mismatch repair enzyme system 
(MMR). Defective DNA MMR usually results from genetic or 
epigenetic alteration in hMLH1 or hMSH2. 
      MSI has been reported in early and advanced gastric cancers 
caused by hypermethylation of the hMLH1 promoter region. Such 
gene inactivation strongly correlates with microsatellite instability- 
high phenotype and results in a loss of protein expression 
identifiable by IHC. 
      The intestinal type is usually associated with microsatellite 
instability. Gastric carcinomas with increased frequency of MSI has 
certain special pathological features such as more antral location of 
the tumour, increased lymphoid infiltrate, minimal lymph node 
metastasis and increased median survival rate. Among the 
European population groups, Rugge showed that DNA repair 
mechanism alterations are early molecular events for gastric 
carcinogenesis and suggested that IHC should be considered as a 
suitable method for MSI assessment in gastric precancerous 
lesions. This may imply that impairment in the function of a repair 
enzyme system may provide a situation for genetic alteration and 
Her-2 overexpression. 
CONCORDANCE BETWEEN HER-2 OVEREXPRESSION 
AND GENE AMPLIFICATION 
         There has been controversial reports regarding the  
concordance of protein expression and gene amplification of Her-2 
in carcinoma stomach. Among 40 cases, Lemoine observed 26% of 
patients had increased protein expression, 13% had gene 
amplification. Kameda also observed the same result in which he 
detected overexpression without amplification and came to a 
conclusion that gene amplification is not only the primary 
mechanism by which Her-2 protein is overexpressed in carcinoma 
stomach. 
 However there are other mechanisms by which Her-2 protein 
is overexpressed which includes  transcriptional activation by other 
genes or post-transcriptional events. ToGA trial showed the 
concordance between Her-2 positivity by IHC and FISH was 85% 
and these results were  largely due to the fact that  FISH positive 
cases  were among those IHC 1+/2+. 
           In 2006, Hoffman considered that differences observed 
between IHC and FISH occurred mainly due to the staining of the 
basolateral membrane of glandular cells increased percentage of 
heterogenous tumours in gastric cancer when compared with breast 
cancer. As a result of these studies they proposed modification in 
assessing Hercep Test score for gastric cancer. 
The Hercep Test TM Kit 
 The Hercep Test is a semi quantitative method  for assessing 
HER2 protein overexpression which was primarily used for breast 
cancer and now modified for using in gastric adenocarcinoma. 
 Following incubation with the primary antibody to human 
HER-2 protein, this kit is ready to be used.  Visualization Reagent 
is based on dextran technology.  This reagent consists of both 
secondary goat anti rabbit molecules and horse-radish peroxidise 
molecules linked to a common dextran polymer backbone, thus 
eliminating the need for sequential application of link antibody and 
peroxides conjugate. The enzymatic conversion of the subsequently 
added chromogen results in formation of a visible reaction product 
at the antigen site.  The specimen may then be counterstained and 
cover slipped.  Control cell in line slides are provided. 
Hercep Test TM test kit consists of the following: 
 Peroxidise – Blocking Reagent 
 Rabbit Anti human HER2 Protein 
 Visualization Reagent 
 Negative control reagent 
 DAB Buffered substrate 
 DAB chromogen 
 Epitope Retrieval solution  
 Wash Buffer (10%)  
  
 
 
Guidelines  for Scoring 
 Her-2 scoring should be performed on the basis of 
pathologist’s previous experience and  judgment for interpreting 
IHC stains. Only biopsy samples from patients with stomach or 
gastroesophageal junction adenocarcinoma should be used for be 
scoring. Those cases containing intestinal metaplasia are not 
considered for scoring. 
SURGICAL SPECIMENS 
Score to 
Report 
HER-2 Protein 
Overexpression 
Assessment 
 
Staining Pattern 
0 Negative  Membranous staning involving less than  
 10% of tumour cell. 
1+ Negative  Membranous staining involving more than 
10% of tumour cells which is faintly 
perceptible. Cells are reactive only in part of 
their membrane. 
2+ Equivocal  Lateral or basolateral membranous staining 
involving more than 10% of tumour cells 
which is weak to moderately complete. 
3+ Positive  Lateral membranous staining involving more 
than 10% of tumour cells which is strongly 
complete. 
 
 
BIOPSY SPECIMENS 
Score to 
Report 
HER-2 Protein 
Overexpression 
Assessment 
Staining Pattern 
0 Negative No staining or membranous staining in any 
tumour cell 
1+ Negative Tumour cell cluster with a faint/barely 
perceptible membranous staining irrespective of 
percentage of  cells stained 
2+ Equivocal Tumour cell cluster with a weak to moderate 
complete, basolateral or lateral membranous 
staining irrespective of percentage of cells 
stained 
3+ Positive Tumour cell cluster with a strong complete, 
basolateral or lateral membranous staining 
irrespective of percentage of  cells stained  
 
 HercepTest should be carried out according to the guidelines 
published in the package insert and within the context of best 
practices and the pathologist’s experience and accurate medical 
judgment. 
 
 
 
ARTIFACTS IN STAINING: 
Edge artifacts 
Edge artifacts are usually linked to the pre-analytic handling 
of the tissue. Often the method of surgical extraction is the cause. 
This phenomenon is more frequently observed for stereotactic 
needle biopsies. 
Increased staining intensity is frequently observed around the 
periphery of the tissue section, known as “the edge effect’. 
The edge effect represents artifacts due to tissue drying prior 
to fixation. If staining is only observed at the edge of the tissue 
section, scoring of the tissue specimen should be avoided. 
Inadequate fixation of tissue samples rendering the central 
portion of the tissue sub-optimal fixed relative to the peripheral 
areas, may mimic edge artifact. In these circumstances, the 
immunoreactivity in the sub-optimal central portion may be 
mistakenly interpreted as false negative as compared to the correct 
immunoreactivity observed at the section periphery which has 
optimal fixation. 
Crush artifacts 
 Crush artifacts are related to edge artifacts.  The artifact may 
be encountered more often in needle biopsies.  It is presumed that 
the tissue injury occurs during the extraction of the tissue from the 
needle rather than from the actual biopsy process.  Regardless, the 
compression of the tissue along the edges of the needle core can 
produce a linear staining that should be interpreted as an artifact. 
 Tissue areas with crushed cells typically demonstrate 
condensed nuclei and should be avoided in scoring.  Deposition of 
the chromogen is characteristic in areas where the cells are crushed, 
while well preserved cells are devoid of immunoreactivity. 
Retraction artifacts  
 Retraction artifacts are small spaces in the tissue where 
antibody and chromogen can pool forming circumferential 
depositions.  Retraction of epithelial cells from stroma may create 
small spaces where the reagent pool around the epithelial cells 
forms a circumferential deposition of the brown end product.  This 
artifact requires thorough examination of the intercellular areas (i.e. 
cell to cell interface not the cell to stroma interface). 
TREATMENT-OVERALL: 
Surgical removal of tumour is the mainstay of treatment for 
both early and advanced stages. Adenocarcinoma is relatively radio 
resistant. Major role of radiotherapy is palliation of pain. 
        The administration of combinations of cytotoxic drugs to 
patients with advanced gastric carcinoma has been associated with 
partial responses in 50% of cases; responders appear to benefit 
from treatment. Such drug combinations have generally included 
cisplatin combined with epirubicin or docetaxel and infusional 5-
FU, or with irinotecan. 
          Despite this encouraging response rate, complete remissions 
are uncommon whereas, the partial responses are transient, and the 
overall influence of multidrug therapy on survival has been unclear. 
The use of adjuvant chemotherapy alone following the complete 
resection of a gastric cancer has only minimally improved survival.  
       However, combination chemotherapy administered before and 
after surgery as well as postoperative chemotherapy combined with 
radiation therapy reduces the recurrence rate and prolongs survival.  
 
Rationale for adjuvant chemotherapy: 
       Because the risk of recurrence with surgery alone is high, the 
use of adjuvant systemic therapy and, in the postoperative setting, 
additional regional treatment with radiation have been extensively 
explored. Two different strategies have been tested: postoperative 
(adjuvant) chemotherapy or chemoradiation therapy or preoperative 
(also known as neoadjuvant or primary) chemotherapy. More 
recently, some clinical trials have begun exploring preoperative 
chemoradiation. 
             The rationale for neoadjuvant therapy is that systemic 
treatment with its attendant risks is best given when a patient is 
most fit to tolerate treatment (i.e., before surgery), that tumour 
regression with neoadjuvant therapy may improve the likelihood of 
an R0 resection, and that the early introduction of systemic therapy 
allows simultaneous treatment of regional and distant disease. In 
contrast, the rationale for postoperative therapy is that higher-risk 
patients will have already been identified by more accurate 
pathologic staging and lower-risk patients will be spared the risks 
for toxicity associated with preoperative treatment based on less 
accurate pre-treatment staging. In addition, because surgery is the 
most effective therapeutic modality, with initial surgical resection 
one would not be taking the risk of giving potentially ineffective 
therapy while delaying effective treatment. 
 
Intraperitoneal chemotherapy 
        The rationale for the use of intraperitoneal chemotherapy after 
resection of primary gastric cancer is the high risk of peritoneal 
metastasis as an initial component of treatment failure. Autopsy 
series and second-look laparotomy series have reported that up to 
50% of gastric cancer patients who undergo potentially curative 
resections have clinically evident peritoneal carcinomatosis as a 
site of failure. 
         
 
Immuno-chemotherapy  
           Japanese and Korean investigators have performed a number 
of trials studying the use of immunochemotherapy as adjuvant 
treatment after curative resection of gastric cancer. Many of these 
trials involve using a protein-bound polysaccharide (PSK) alone or 
combined with chemotherapy after gastrectomy. PSK is a 
polysaccharide extracted from Coriolis vesicular, whose 
mechanism of action is not fully understood. The control arm in 
most of these studies, however, also received chemotherapy.       
               Nakazato et al. reported the results of a study involving 
patients who were randomly assigned to receive mitomycin plus 
FU (given by mouth) or the same chemotherapy plus PSK. The 
experimental arm received treatment with PSK for 36 months after 
surgery. As part of the eligibility process, patients had to have a 
positive purified protein derivative of tuberculin (PPD) test. Both 
groups received ten cycles of chemotherapy. With a minimum 
follow-up of 5 years, a significant survival advantage was seen for 
the PSK group. 70% of the PSK group versus 59% of the standard 
treatment group were alive and disease free at 5 years.  
            In other trials, Korean investigators have studied the use of 
chemotherapy plus immunostimulants after potentially curative 
resection. In one trial, chemotherapy with mitomycin, FU, and 
cytosine arabinoside plus OK432 (a Streptococcus pyogenes 
preparation) was given to 74 patients, whereas a control group of 
64 patients underwent surgery alone. 265 Of the group receiving 
postoperative treatment, 44.6% were alive at 5 years, compared to 
23.4% of those randomized to surgery only. In a follow-up three-
arm trial, patients were randomized to receive immunotherapy with 
OK432 plus chemotherapy with mitomycin and FU. A second 
group received chemotherapy alone, whereas the third arm was a 
control arm of observation after surgery. At 5 years, 45.3% of the 
immunochemotherapy group were alive, compared to 29.8% of the 
chemotherapy group and 24.4% of the surgery group. Kim et al. 
performed a similar trial using FAM chemotherapy with or without 
OK432. Fifty patients received chemotherapy alone, and 49 
patients received chemotherapy plus OK432. These authors 
reported a significant improvement in survival for chemotherapy 
plus immunotherapy versus chemotherapy alone . 
           In summary, data from Japanese and Korean investigators 
suggest that immunotherapy may improve outcome for patients 
undergoing potentially curative resection. The number of patients 
in any given trial is small, and it is unclear how these trials should 
be translated to Western patient populations.  
 
COMBINATION CHEMOTHERAPEUTIC DRUGS 
FAM and FAMTX 
The FAM combination was widely used for metastatic gastric 
cancer in the 1980s but is rarely used in current clinical practice. 
Phase III trials failed to demonstrate a significant improvement in 
survival with FAM, and the response rates in those trails were 
substantially lower than the rates reported in the initial studies of 
FAM. 
        Substitution  of FU by methotrexate and leucovorin led to the 
development of the FAMTX regimen. Phase II studies in patients 
with metastatic gastric cancer indicated high response rates to 
FAMTX, and phase III studies comparing FAMTX with etoposide, 
doxorubicin, and cisplatin (EAP) showed FAMTX to be better 
tolerated. These led to a European Organization for Research and 
Treatment of Cancer study comparing FAMTX and the older FAM 
regimen. The response rate with FAMTX was superior to that with 
FAM. The 2-year overall survival rate for patients receiving 
FAMTX was 9%, compared with 0 for those receiving FAM; this 
was not better than the rate expected with the best supportive care. 
Subsequently, FAMTX was found to be inferior to cisplatin-
containing combinations, and it is not widely used currently. 
Cisplatin-Based Chemotherapy 
Although many phase II studies of cisplatin-containing 
regimens have been performed, only a few RCTs have been 
reported. Several recent trials have compared cisplatin-based 
combinations to non-cisplatin-based combinations, allowing a 
fuller evaluation of these regimens. 
The in vitro synergy between cisplatin and FU, the activity of 
cisplatin as a single agent in gastric cancer, and the potential 
advantage of cisplatin over older drugs such as mitomycin C led to 
the development of cisplatin-FU regimens. Response rates to many 
of these regimens are in the 30% to 50% range. For example, the 
cumulative overall response rate for FU, doxorubicin, and cisplatin 
(FAP) is approximately 35%. As is the case for other combinations, 
only 3% to 5% of patients achieve complete clinical remissions. 
Cunningham et al. substituted epirubicin for doxorubicin in the 
ECF combination (epirubicin, cisplatin, and FU). In phase II trials 
of ECF, the overall response rate ranged from 37% to 71%. 
These preliminary results led Waters et al. to perform a 
comparison of ECF to FAMTX. In a randomized MRC study, 126 
patients received ECF and 130 patients received FAMTX. The 
overall response rate for ECF was significantly higher than that for 
FAMTX . Median survival was also longer for ECF (8.7 vs. 6.1 
months). In an update by Waters et al., the 2-year overall survival 
rate was 14% for patients receiving ECF versus 5% for those 
receiving FAMTX. 
Ross et al.  performed a two-arm randomized trial comparing 
ECF (289 patients; reference arm) to mitomycin, cisplatin, and 
protracted infusional FU (MCF; 285 patients). The trial allowed 
entrance of patients who had esophageal or gastric cancers, and the 
overwhelming majority of patients had adenocarcinoma. Patients 
with locally advanced disease were also allowed to take part; only a 
small percentage of these patients subsequently underwent 
operation. 
 No significant difference was seen in response (42% for ECF 
vs. 44% for MCF), median survival (9.4 months vs. 8.7 months), or 
1- and 2-year overall survival rates. The analysis included a 
quality-of-life assessment in which ECF was generally superior to 
MCF. The authors concluded that ECF should continue to be one of 
the reference treatments for advanced esophagogastric cancer. 
Cisplatin-Etoposide Variants 
     Because etoposide and cisplatin may be synergistic, these 
drugs have been combined in the treatment of many tumors. 
Several phase II studies in patients with metastatic gastric cancer 
demonstrated that the combination is well tolerated. Preusser et al. 
then added doxorubicin to create the EAP regimen. Phase II trials 
of EAP reported high response rates. In subsequent phase III 
studies, although response rates of approximately 50% were 
reported, toxicity was high, with treatment-related mortality 
ranging between 10% and 14%. In a randomized comparison of 
EAP to FAMTX, Kelsen et al. showed similar response rates for 
the two regimens but significantly less toxicity with FAMTX. 
Wilke et al. developed etoposide, leucovorin, and 5-FU 
(ELF). Because of the toxicity of EAP, particularly in older 
patients, phase II study data indicated a substantial response rate, 
approximately 50%, and a median duration of response of 9 to 10 
months. ELF was subsequently studied in phase III trials . 
Cisplatin-Fluorouracil 
The combination of 5FU and Cisplatin are extensively 
studied in gastric cancer. Phase II studies very good response with 
minimal toxicity. This regimen has been considered by some U.S. 
investigators to be a reference regimen and typically consists of 75 
to 100 mg/m
2
 cisplatin and 750 to 1000 mg/m
2
 FU given as a 4 or 5 
day infusion. 
Two phase III randomized studies compared cisplatin-FU to 
other regimens. Vanhoefer et al. compared ELF, cisplatin-FU, and 
FAMTX in 399 patients with advanced gastric cancer. No 
significant differences were seen in response rates among the 
patients with measurable disease (9% for ELF, 20% for cisplatin-
FU, and 12% for FAMTX). Also, no differences were found in 
median survival, which ranged from 6.7 to 7.2 months.  
      Ohtsu et al. compared cisplatin-FU to FU alone and to uracil 
and tegafur (UFT) plus mitomycin C in 280 Japanese patients with 
unresectable advanced gastric cancer. The UFT-mitomycin arm 
was inferior and was closed after an interim analysis. The overall 
response rate was higher for cisplatin-FU (34%) than for FU alone 
(11%) or for UFT-mitomycin (9%), as was the progression-free-
survival rate. However, there was no difference in overall survival.  
Docetaxel-Containing Therapy 
       Phase II trial results for taxane-containing, irinotecan-
containing, and oxaliplatin-containing regimens are being reported, 
but there are no reports of completed phase III trials involving these 
regimens. Interim results of one randomized study comparing a 
docetaxel, cisplatin, and FU regimen to a cisplatin and FU regimen 
have been reported in abstract form. In this study, Ajani et al. 
compared 75 mg/m
2
 docetaxel with 75 mg/m
2
 cisplatin on day one 
plus 750 mg/m
2
/d FU by continuous intravenous infusion over 5 
days every 3 weeks with 100 mg/m
2
 cisplatin followed by a 5-day 
infusion of 1000 mg/m
2
 FU every 4 weeks. The result of this study 
showed good response  with increase in median survival rate. At 
the time of the interim analysis, 111 patients receiving the three-
drug regimen and 112 receiving the two-drug regimen had been 
analyzed. A significantly higher time to tumor progression was 
reported for the docetaxel, cisplatin, and FU arm. The response and 
survival rates also appear to be higher in this arm. But the end 
result of this was not reported. 
Another area of investigation is the use of irinotecan-
containing regimens. Preliminary results of a randomized phase II 
trial comparing cisplatin and irinotecan to irinotecan, FU, and 
leucovorin have been reported. Both of these combinations were 
found in earlier studies to have substantial response rates. In this 
study, the two arms (approximately 70 patients in each) were well 
balanced for major prognostic variables. Toxicity was slightly 
greater in the cisplatin-irinotecan arm, and the overall response rate 
was higher and median survival longer for patients receiving 
irinotecan, FU, and leucovorin. Therefore, the three-drug arm was 
chosen for a definitive phase III trial comparing it to cisplatin-FU. 
This study has completed the accrual, and no data are available at 
this time. 
         In addition to new classes of cytotoxic agents, there is also 
interest in the use of oral fluorinated pyrimidines. These are FU 
prodrugs that offer the ease of oral administration and mimic the 
benefits of long-term infusional therapy. Different mechanisms of 
action offer another advantage. Three fluorinated pyrimidines have 
been studied in gastric cancer as single agents: UFT, S1, and 
capecitabine. In most studies, the overall response rate for all three 
drugs is approximately 20% to 30%, similar to the rate reported in 
the past for FU. Whether the oral fluoropyrimidines are equivalent 
to infusional FU in gastric cancer is not yet clear. 
TARGETED THERAPY 
Anti Her-2 therapy has been found to increase the survival of 
patients who express Her-2 receptor in carcinoma stomach. Two 
groups of drugs that act against EGFR and HER-2 are increasingly 
used to prolong the survival in gastric cancer. 
1. Monoclonal antibodies, 2. Tyrosine kinase inhibitors 
 Monoclonal antibodies: It acts by three mechanism 
1. Blocks the intracellular cascade by inhibiting ligand – 
receptor binding. 
2. Decreasing the expression of receptors on cell surface by  
 downregulation of receptors and endocytosis. 
3. Activation of immune system and complement by inducing  
     Antibody dependent cell cytotoxicity ( ADCC). 
Drugs commoly used are Cetuximab, Panitumumab, Matuzumab, 
Nimotuzumab, Trastuzumab. All these drugs are administered by 
intravenous infusion. 
Tyrosine kinase inhibitors: 
       It acts by preventing the binding of ATP with tyrosine kinase 
domain and inhibits the autophosphorylation of EGFR and HER-2. 
        Drugs used in trial are Erlotinib, Geftinib, Lapatinib. 
 
Cetuximab 
          Cetuximab has been tried as monotherapy in both oesophageal 
and gastric cancer. But the response rate was found to only 20 to 30 
percent. Cetuximab on combination with other chemotherapeutic 
regimes showed response rate of 50 to 60 percent with median 
survival of 10 months. Three trials were conducted with 
combination of cetuximab. FOLFOX, ECF, Irinotecan and cisplatin 
were combined with cetuximab. Response rate of 50 percent was 
achieved only  with ECF and FOLFOX combination with median 
survival of 6 months.  
           In advanced gastric cancer, it has been tried as a 
chemosensitivity restoring agent, but the response was poor. 
Cetuximab has also been tried in patients with metastatic colorectal 
cancer. The main toxicity profile was skin rash and diarrhoea. 
Panitumumab 
            Panitumumab is a humanized  IgG2 monoclonal antibody used 
in combination with Oxaliplatin and Capecitabine. The response 
rate was found to be inferior when compared with cetuximab. 
Diarrhoea is the predominant side effect. 
Matuzumab 
       Matuzumab is a humanized IgG1monoclonal antibody directed 
against EGFR which acts by ADCC. Results of various trials 
showed Matuzumab had showed lower response rate and poor 
survival both as monotherapy and combination therapy. As a result 
it is not recommended for treatment of advanced gastric cancer. 
Nimotuzumab 
         Nimotuzumab is a humanized IgG1 monoclonal antibody 
used both as monotherapy and combination with Irinotecan. The 
median survival with combination therapy was lower on compared 
with Irinotecan alone. 
Trastuzumab 
       Trastuzumab is a humanized IgG1 monoclonal antibody. It is 
used as combination therapy with either cisplatin or cisplatin and 
docetaxel. Tumours which expressed Her-2 positivity either by 
using IHC or FISH were enrolled for this combination therapy.  
         Preliminary trials were satisfactory with good subjective 
response and minimal side effects which paved way for ToGA trial. 
3665 patients with GEJC and gastric cancer who tested Her-2 
positivity were randomly assigned into two groups. The control 
group received only chemotherapy with cisplatin, 5 FU, 
capecitabine and the study group received chemotherapy with 
above drugs and trastuzumab. 
                The response rate and median survival was significantly 
high in patients receiving trastuzumab with chemotherapy but side 
effect profile diarrhoea was found to be higher in trastuzumab  
group. As a result of these studies trastuzumab was approved by 
FDA for treating Her-2 positive advanced gastric cancer.  
Lapatinib 
          Results of ToGA trial led to the development of another anti 
Her-2 agent Lapatinib. It induces G1 cell cycle arrest through AKT 
and MAPK pathways. The overall survival was poor when 
Lapatinib was used as a monotherapy. The response rate was 25 
percent when it was combined with Capecitabine. The role of  
Lapatinib in Her-2 negative cases is also being studied. TYTAN 
trial compares the efficacy of Paclitaxel with and without 
Lapatinib. LOGiC trial compares Capecitabine and Oxaliplatin 
with and without Lapatinib in Her-2 positive cases. Results of both 
these studies are awaited. 
The HercepTest  identifies Her-2 overexpression in patients 
with both carcinoma stomach and carcinoma breast. As a result of 
this, it was approved by FDA for treatment with Trastuzumab. 
         Her-2 overexpression  has been designed into four 
levels:0,1,2,3. Trastuzumab do not show any response in patients 
with level 0 and 1. Level 2 expression has some benefit. Patients 
who express level 3 shows significant responseby increase in 
median survival and overall response rate.       
       Trastuzumab when combined with Doxorubicin was associated 
with increased of heart failure. Fatal infusion reactions and 
pulmonary fibrosis were also described with trastuzumab. The 
infusion reaction occurred within 24 hours of infusion.  
Trastuzumab infusion should be stopped for patients with dyspnoea 
or clinically significant hypotension.  Patients should be monitored 
until signs and symptoms completely resolve.  Trastuzumab is 
contraindicated in those patients manifesting as anaphylaxis, 
diarrhoea, angioneurotic oedema, interstitial lung disease and acute 
respiratory distress syndrome. 
       The standard initial dose of  Herceptin  is 8 mg/kg as a 90-min 
intravenous infusion which is subsequently followed by doses of 
6mg/kg as an intravenous infusion over next 30 to 90 mins and 
repeated every 3 weeks until disease progression.  
Predicting Response to treatment 
 
        The development of techniques that will allow physicians to 
prospectively choose chemotherapeutic agents that are most likely 
to work in an individual patient is a high priority. This is 
particularly important because currently available cytotoxic 
chemotherapy for gastric cancer has only modest to moderate 
effectiveness, with objective regressions in 25% to 40% of all 
patients treated, and toxicities can be substantial. In vitro assays of 
live tumor cells have not proved to have adequate sensitivity; 
however, several studies have suggested that molecular analysis of 
tumor tissue might provide a more accurate predictor of outcome. 
The hypothesis is that levels of expression of molecular targets or 
of molecules associated with the mechanism of action of an 
individual agent are associated with response or resistance. 
           Preliminary studies of several new techniques for molecular 
analysis have been performed in gastric cancer. These studies were 
generally retrospective evaluations of prospectively accrued data 
and tissue. For example, the majority of correlative studies have 
involved collecting tissue before therapy, treating a group of 
patients with the same treatment (e.g., cisplatin-FU chemotherapy), 
and then correlating the molecular analysis findings with clinical 
outcome. In some cases, tissue has been collected at the time of 
definitive surgery after initial chemotherapy and these studies are 
more difficult to evaluate because the correlative analysis is 
performed after treatment. 
           The molecular analysis approaches used to date include 
evaluation of single genes or small numbers of genes by 
immunohistochemistry or by the use of reverse transcriptase 
polymerase chain reaction. Gene expression profiling involving 
hundreds or thousands of genes has also been studied. These 
techniques are being explored extensively for cancers in general, 
but data on their use in gastric cancer are limited.  
              Most of the data currently available involve small groups 
of patients treated with preoperative chemotherapy in whom 
molecular analysis of pre-treatment  biopsy specimens and post 
treatment surgically resected tissue is performed. In older trials 
from the University of Southern California, Metzer et al. and Lenz 
et al. reported on an analysis of a subgroup of patients who 
received neoadjuvant cisplatin-FU chemotherapy, followed by 
resection and intraperitoneal floxuridine. 
            Response and survival were correlated with molecular 
markers assessed by reverse transcriptase polymerase chain 
reaction for several genes of interest, primarily thymidilate 
synthase (TS) and ERCC1 (excision repair cross complementing 
gene), a putative marker of cisplatin sensitivity. Patients with low 
levels of relative expression of these two genes had a significantly 
longer median survival and higher long-term survival rate than did 
patients with high levels of expression. 
         
Drug resistance 
           Resistance to chemotherapy has been reported by many 
investigators to be associated with mutations of the p53 oncogene. 
Several studies of this association have been performed in gastric 
cancer. Cascinu et al.  performed immunohistochemical analysis of 
pre-treatment  endoscopic biopsies from 30 patients with locally 
advanced but not metastatic gastric cancer. 
            Assessing response to treatment in such patients can be 
difficult, but 10 of 12 responding patients had p53-negative tumors, 
whereas patients overall had high levels of p53 expression. A 
definitive study in which adequate numbers of patients with 
advanced gastric cancer receive the same chemotherapy 
irrespective of their molecular marker profile and are followed 
prospectively has not yet been performed. 
Histopathologic Assessment of Response 
        
         The use of preoperative systemic therapy has led to an interest 
in evaluating histologic changes as a surrogate marker of efficacy. 
Histologic assessment of response typically includes identification 
of residual cancer cells and determination of the extent of fibrosis. 
In one study, a tumor regression scale of grades 1 to 5 was used, 
with 1 denoting a complete pathologic regression and 5 meaning no 
evidence of chemotherapy effect. 
            Regression was defined by the replacement of cancer with 
fibrous tissue and scattered inflammatory cells. Percent histologic 
response was determined, ranging from no evidence of treatment 
effect (0%) to a complete response with no viable tumor identified 
(100%). Complete or near complete responses were associated with 
improved long-term survival rates. 
         The use of immunohistochemistry in assessing treatment 
response has also been evaluated. In one study, p53, Ki-67, and 
epidermal growth factor receptor expression were the most reliable 
tissue markers of response. Initial evaluations of the induction of 
apoptosis by chemotherapy in gastric cancer have used the TUNEL 
assay. Satomi et al. correlated traditional assessment of histologic 
response and TUNEL assay findings. However, the use of histology 
as a surrogate for therapeutic effect is still an experimental 
approach. 
Positron Emission Tomography and Treatment Response 
           
            Another potential role for FDG-PET is the evaluation of 
treatment response. A growing body of evidence suggests that 
FDG-PET can be used to identify response to therapy early in 
treatment. This approach has been studied in several tumours, 
including non-Hodgkin's lymphoma, breast cancer, and tumours of 
the gastroesophageal junction. In these studies, PET was used to 
assess response to chemotherapy or to chemo radiation, and results 
were correlated with histology, traditional imaging modalities, and 
survival. 
             The positive and negative predictive values for FDG-PET 
for histologic response were 77% and 86%, respectively. The 2-
year overall survival rates of PET responders versus PET 
nonresponders were 89% and 26%. Many studies  concluded that a 
significant decrease in FDG-PET SUV identified at day 14 is 
associated with histologic response and with survival. 
FISH ASSAY:     
        Apart from IHC, FISH assay is also used for standardization of 
Trastuzumab therapy. It allows direct visualisation of the gene as it 
contains direct labelled DNA probe that binds to Her-2 gene. FISH 
assay approved by FDA quantifies Her-2 amplification. The 
HER2/neu is also over-expressed in other tumours  like ovarian, 
bladder, pancreatic, salivary gland, endometrial and non-small-cell 
lung cancer.  
 
 
 
                
 
 
                    METHODS AND MATERIALS 
          Thirty gastric adenocarcinoma patients paraffin block was 
obtained from Department of Pathology, Madurai Medical College. 
It consists of both surgical and biopsy block. All patients had 
undergone supra and infra diaphragmatic imaging studies with 
chest X-ray, Ultrasound abdomen, CT abdomen and chest. TNM 
staging had bee n performed on all patients according to American 
Joint Committee on Cancer. Ten patients undergone surgery 
followed by chemotherapy and remaining twenty patients were 
receiving palliative chemotherapy. 
       Representative blocks were chosen for immunostaining. IHC 
was performed with Hercep test kit. Tumour with more than ten 
percent of cancer cells showing membranous staining for Her-2 
were classified as positive. 
 
 
                
                 RESULTS AND OBSERVATIONS 
TABLE – 1: AGE DISTRIBUTION 
 
 
          
         AGE(in yrs) 
Her-2/ neu status Total 
 Positive Negative 
 
20-40 2 3 5 
41-60 4 14 18 
61-80 1 6 7 
Total 7 23 30 
 
 
Out of 30 patients, Her 2 positivity reported was 7. Among 
seven patients, maximum positivity was seen in age group between 
41 to 60, this is because maximum number of cases were reported 
in these age groups. The P value was 0.695 which was not 
statistically significant on comparing with other age groups.        
 
TABLE 2: SEX DISTRIBUTION 
 
 
 
SEX 
Her-2/ neu status Total 
 Positive Negative 
 
Male 5 17 22 
Female 2 6 8 
Total 7 23 30 
 
 
Of the 30 patients, male to female ratio was 2.75.this is 
because cancer stomach is more common in males on compared to 
females Among 22 males, 5 showed positivity and among 8 
females, 2 showed positivity, the ratio was 2.5. The P value was 
1.000 which was not statistically significant. Also on comparing 
males and females individually with positive and negative results to 
their total, P value obtained was 0.063 (males) and 0.464 (females) 
which was not significant. 
 
TABLE 3: TUMOUR  GRADING 
 
 
 
GRADING 
(differentiation) 
 
Her-2/neu status Total 
 Positive Negative 
 
Poor 2 8 10 
Moderate 4 7 11 
Well 1 8 9 
Total 7 23 30 
 
 
Out of 30 patients, all three types of grade were almost 
equally present. Among 7 positive patients, maximum cases belong 
to moderate differentiation, on comparing with other two, the P 
value was 0.494 which was not statistically significant. 
 
 
TABLE 4: TUMOUR (T) - STAGING 
 
 
 
T stage 
Her-2/neu status Total 
 Positive Negative 
 
T1,2,3 1 8 9 
T4 6 15 21 
Total 7 23 30 
 
 
 
Out of 30 patients, 21 patients belonged to T4. This shows 
that maximum number of patients were diagnosed in advanced 
stage. Her2 positivity was also maximum in T4. On comparing 
with T1,2,3 the  P value was 0.393 which was not statistically 
significant. Also on comparing the positive and negative results of 
T4 the P value was 0.177 which was not statistically significant. 
 
 
  
TABLE 5: NODE (N) - STAGING 
 
 
 
N stage 
Her-2/neu status Total 
 Positive Negative 
 
N0 3 7 10 
N1 4 9 13 
N2 0 6 6 
N3 0 1 1 
Total 7 23 30 
 
Among 30 patients, 23 patients belong to N0 and N1. All the 
7 patients tested positive comes among the above 23. None of 
patients from N2 and N3 tested positive. The P value was 2.724 
which was not statistically significant. 
 
 
 TABLE 6: METASTASIS (M) - STAGING 
 
 
M stage 
Her-2/neu status Total 
 Positive Negative 
 
M0 3 16 19 
M1 4 7 11 
Total 7 23 30 
 
 
 Out of 30 patients, 11 patients had distant metastasis, Among 11 
patients, 4 showed Her2 positivity. But among 19 patients who had 
no metastasis, 3 showed positivity. This shows that positivity was 
equally distributed among patients irrespective of metastasis. The 
statistical P value was 0.372 which was not significant.  
 
 
 
 TABLE 7:  TNM STAGING  
 
 
STAGING 
Her-2/neu status Total 
Positive Negative 
 
Stage 1 1 1 2 
Stage 2 0 9 9 
Stage 3 2 6 8 
Stage 4 4 7 11 
Total 7 23 30 
 
 
Although the number of patients in stage 2,3,4 were almost 
equally distributed , maximum positivity was present in stage 4. 
Two patients were positive among 8 belonging to stage 3. The 
statistical P value was 0.163 which was not significant. 
 
 
 
 TABLE 8 : HISTOLOGY   
 
 
 
 
HISTOLOGY 
Her-2/neu status Total 
 Positive Negative 
 
Intestinal 7 22 29 
Diffuse 0 1 1 
Total 7 23 30 
 
     Among 30 patients, 29 patients belong to intestinal sub-type. 
All 7 positive patients were from above 29. This shows that Her2 
positivity was maximum from intestinal sub-type of gastric cancer, 
but the statistically P value was not significant. This is because the 
number of patients belonging to diffuse type was less.  
 
 
 
 TABLE 9 – HER-2 POSITIVITY 
 
Study No.of cases Positive 
Percentage 
Yano et al 200 23% 
Gravalos et al 166 13% 
Lordick et al 1527 22% 
ToGA trial 3665 22% 
Our study 
 (GRH, Madurai) 
30 23% 
 
On comparing with various studies conducted all over the 
world, our study (GRH, MADURAI) showed SIGNIFICANT 
positivity. Among 30 patients studied, 7 patients tested positive for 
Her 2 by IHC. The percentage positivity was 23.3. 
 TABLE 10: PROGNOSIS 
 
Prognosis No.of cases Death 
Positive 7 7 
Negative 23 5 
 
  Among 7 patients who tested positive died within one year of 
follow-up inspite of effective chemotherapy and surgical measures. 
This indicates that Her2 positive patients has poor prognosis inspite 
of effective treatment. Among 23 patients who were negative, 5 
patients died during follow-up for one year, it indicates that staging 
is also important in prognostic significance. The statistical P value 
was 0.047 which was SIGNIFICANT. 
 
 
DISCUSSION 
            Tumours of the upper gastrointestinal tract have been 
reported to show a wide range of overexpression of HER-2 protein. 
In our study we investigated the expression of this receptor protein 
in 30 patients in GRH MADURAI retrospectively. Our observed 
prevalence of HER2 protein overexpression by IHC was 23% 
which fits the range previously reported (8.2%- 27.5% ). 
          However, at the upper range there are some limitations 
inherent in IHC technique, such as those caused by variability in 
fixation, and different standardization techniques  and scoring of 
the staining. The results of ToGA trial analysed by FISH technique 
showed HER-2 was found to be amplified in about 18% of cases. 
Our percentage can be modified as well if we employ FISH method 
alternative to IHC on the same samples. This is designed as the 
future direction of this project.  
           The results of ToGA trial showed that the intestinal type of 
carcinoma stomach shows higher prevalence of HER2 
amplification in contrast to diffuse type. But our results failed to 
confirm that HER2 Protein overexpression is strongly associated 
with intestinal subtype than diffuse subtype. However, so far none 
of the studies evaluated the clinical importance of this feature. 
            HER2 gene amplification has been associated with the 
degree of differentiation of adenocarcinomas, in that well 
differentiated adenocarcinomas have shown a very high incidence 
of HER2 amplification. In our study, moderately differentiated 
tumours were more likely to overexpress HER-2 protein. However, 
not all studies agree, and a positive relation with poor tumour 
differentiation has been reported as well. 
             Further in our study, HER2 positivity does not correlate 
with the AGE, SEX and TNM staging which was already proven in 
various studies. Relating to prognosis, none of the seven HER2 
POSITIVE patients survived beyond one year of follow-up of 
study, which showed HER2 overexpression as a poor prognostic 
factor. On the other hand five patients with HER--2 NEGATIVITY 
also died during follow-up, which showed surgical stage is by itself  
another  proven prognostic factor status . The absence of 
correlation between HER-2 expression status and staging might be 
due to the fact that HER-2 positive tumours have a more aggressive 
pathologic behaviour, which is reflected in more common 
micrometastatic  disease at presentation and more distant failures 
later after treatment. 
       Additionally, it should be noted that there are inconsistencies 
in the literature regarding the clinical significance of HER2 
overexpression which may be due to problems of selecting the best 
methodology, standardizing techniques, and determination of 
appropriate cut off points. 
 
 
 
 
 
 
                            
                           CONCLUSION 
          Gastric cancer is one of the leading causes of cancer 
mortality in INDIA. This is due to the fact that most of the patients 
were diagnosed at end stage where only palliation is possible. In 
patients where surgical resection is not possible, systemic 
chemotherapy is the main treatment option. 
       Although many chemotherapeutic regimes have been 
extensively studied both as monotherapy  and combination therapy  
active in metastatic diseases, there is no internationally accepted 
standard of care and survival remains poor. In order to increase the 
life span newer therapeutic strategies are needed. There is 
increasing evidence that HER2 overexpression in patients with 
gastric cancer is correlated with poor outcomes and more 
aggressive disease.  
         Various trials showed TRASTUZUMAB inhibits the growth 
of human gastric cancer in patients with HER2 overexpression both 
in vitro and vivo.  These clinical trials paved way for starting 
ToGA trial which was studied in gastric cancer patients conducted 
in various countries all over the world. The results of these studies 
will contribute to a better knowledge of the efficacy and treatment 
of TRASTUZUMB- based therapy in HER2 POSITIVE gastric 
cancer in the future. 
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PROFORMA 
NAME  : 
AGE/SEX  : 
OCCUPATION : 
ADDRESS  : 
GENERAL EXAMINATION : 
 Anaemia, Jaundice 
    Lymph nodes 
    Pedal oedema 
SYSTEM EXAMINATION : 
CVS  : 
RS  :  E/O Pleural effusion 
ABDOMEN:  E/O Hepatic secondaries, ascitis,  
epigastric mass 
CNS  : 
 
OTHER  SYSTEMS :  E/O Cutaneous metastasis,  
acanthosis nigricans. 
INVESTIGATIONS : 
X-RAY CHEST 
ULTRASOUND ABDOMEN AND PELVIS 
CT ABDOMEN AND THORAX 
ENDOSCOPY 
PARAFFIN BIOPSY BLOCK 
STAGING: TNM 
 
 
 
 
 
 
ABBREVIATIONS 
Her 2  -  Human epidermal growth factor receptor 2 
ERBB 2 -  Erythroblastic leukemia viral oncogene homolog 2 
H.pylori -  Helicobacter pylori 
IARC -  International Agency for Research on cancer 
ACS  -  American cancer society 
MSI  -  Microsatellite instability 
ToGA -  Trastuzumab for gastric cancer 
FISH  -  Fluorescent in-situ Hybridisation 
TKI’s -  Tyrosine kinase inhibitors 
MAbs -  Monoclonal antibodies 
CRC  -  Colorectal cancer 
ASCO -  American society of clinical oncology 
EMA  -  European medicines agency 
ADCC -  Antibody dependent cell cytotoxicity 
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1 Sathan 50 M INTESTINAL MUSCLE NO NO 
STAGE 
1B T2 N0 M0 3+ MOD DIFF 
2 KALYANI 40 F INTESTINAL SEROSA COELIAC, PARA AORTIC LIVER STAGE 4 T4a N1 M1 3+ WELL DIFF 
3 ABBAS 53 M INTESTINAL SEROSA PERIGASTRIC NO 
STAGE 
3A T4a N1 M0 3+ MOD DIFF  
4 NALLIAH 63 M INTESTINAL SEROSA NO LIVER STAGE 4 T4a N0 M1 3+ MOD DIFF  
5 SELVI 35 F INTESTINAL SEROSA  10 PERIGASTRIC NO 
STAGE 
3A T4a N1 M0 3+ 
POORLY 
DIFF 
6 AYEPILLAI 50 M INTESTINAL SEROSA HEPATODUODENAL LIVER STAGE 4 T4b N1 M1 3+ MOD DIFF  
7 SOMASUNDARAM 51 M INTESTINAL SEROSA NO 
PLEURAL 
EFFUSION STAGE 4 T4b N0 M1 3+ 
POORLY 
DIFF 
8 KANDASAMY 76 M INTESTINAL SEROSA COELIAC NO 
STAGE 
3A T4a N1 M0 2+ MOD DIFF  
9 MUTHURAJ 74 M INTESTINAL SEROSA COELIAC NO 
STAGE 
3A T4a N1 M0 2+ MOD DIFF  
10 BALAMMAL 50 F INTESTINAL MUSCLE 3/6 NODES NO 
STAGE 
2B T2 N2 MO 2+ WELL DIFF 
11 ALAGAR 45 M INTESTINAL SEROSA NO PERITONEAL 
 STAGE 
4 T4a NO M1 2+ MOD DIFF  
12 MUNIANDI 63 M INTESTINAL SEROSA 3/13 NODES LIVER STAGE 4 T4a N2 M1 2+ MOD DIFF  
13 KARUPIYA 50 M INTESTINAL SEROSA 3/7 NODES NO 
STAGE 
3B T4a N2 M0 2+ 
POORLY 
DIFF 
14 PERUMAL 50 M INTESTINAL SEROSA NO NO 
STAGE 
2B T4a NO M0 2+ WELL DIFF 
15 MACHAKALAI 52 M INTESTINAL SEROSA COELIAC, PERIGASTRIC NO 
STAGE 
3A T4a N1 M0 2+ WELL DIFF 
16 ANTHONY 61 M INTESTINAL SEROSA 2/4 NODES NO 
STAGE 
2A T2 N1 M0 2+ 
POORLY 
DIFF 
17 MUTHIAH 41 M INTESTINAL MUSCLE 
COELIAC, PERI 
PANCREATIC NO 
STAGE 
2A T2 N1 M0 2+ 
POORLY 
DIFF 
18 MUTHUMANI 67 M INTESTINAL SEROSA PORTAL LIVER STAGE 4 T4a N1 M1 2+ WELL DIFF 
19 PANCHAVARNAM 45 F INTESTINAL MUSCLE COELIAC, PERIGASTRIC LIVER STAGE 4 T2 N2 MI 1+ 
POORLY 
DIFF 
20 VALLIAMMAL 66 F INTESTINAL SEROSA NO NO 
STAGE 
2B T4a N0 M0 1+ 
POORLY 
DIFF 
21 POONGODI 48 F INTESTINAL MUSCLE NO NO 
STAGE 
1B T2 N0 M0 1+ MOD DIFF  
22 MURUGESAN 38 M INTESTINAL SEROSA OMENTAL NO 
STAGE 
3A T4a N1 M0 1+ MOD DIFF  
23 PONNIAH 60 M INTESTINAL SEROSA 3/7 NODES LIVER STAGE 4 T4a N2 M1 1+ WELL DIFF 
24 THARMAR 27 M DIFFUSE SEROSA NO NO 
STAGE 
2B T4a N0 M0 1+ 
POORLY 
DIFF 
25 SARKARAI ABDUL 30 M INTESTINAL MUSCLE 6/7 NODES NO 
STAGE 
2B T2 N2 M0 1+ WELL DIFF 
26 MARIAPPAN 45 M INTESTINAL SEROSA COELIAC  ASCITIS STAGE 4 T4a N1 M1 0 
POORLY 
DIFF 
27 JANAKI 42 F INTESTINAL SEROSA 7/8 NODES NO 
STAGE 
3C T4a N3 M0 0 WELL DIFF 
28 GURUVAMMAL 42 F INTESTINAL SEROSA NO NO 
STAGE 
2B T4a N0 M0 0 WELL DIFF 
29 RAMASAMY 60 M INTESTINAL MUSCLE PERIGASTRIC ASCITIS STAGE 4 T2 N1 M1 0 MOD DIFF  
30 KARUPIAH 60 M INTESTINAL SEROSA NO NO 
STAGE 
2B T2 N0 M0 0 
POORLY 
DIFF 
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